Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(12):1987–1994. doi: 10.1038/sj.bjc.6690632

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

J Schneider 1, P Presek 2, A Braun 2, P Bauer 3, N Konietzko 3, B Wiesner 4, H-J Woitowitz 1
PMCID: PMC2363153  PMID: 10471051

Abstract

The oncogene product epidermal growth factor receptor (EGF-R), the tumour suppressor gene product p53 and anti-p53 antibodies are detectable in the serum of certain cancer patients. Increased levels of some of these products were reported in lung cancer patients after occupational asbestos exposure and after exposure to polycyclic aromatic hydrocarbons or vinylchloride. In the first step, this study investigated the possible diagnostic value of serum EGF-R, p53-protein and anti-p53 antibodies, measured by an enzyme-linked immunosorbent assay, in lung tumour patients. In addition to being investigated on a molecular epidemiological basis, these parameters were examined as biomarkers of carcinogenesis, especially with regard to asbestos incorporation effects or of radon-induced lung cancers. Also, a possible effect of cigarette smoking and age dependence were studied. A total of 116 male patients with lung or pleural tumours were examined. The histological classification was four small-cell cancers, six large-cell cancers, 32 adenocarcinomas, 47 squamous carcinomas, 12 mixed lung carcinomas, five diffuse malignant mesotheliomas and ten lung metastasis of extrapulmonary tumours. Twenty-two lung cancers and all mesotheliomas were related to asbestos, 22 lung cancers were related to ionizing radiation and 61 patients had cigarette smoke-related lung cancer. Besides these patients 50 male patients with non-malignant lung or pleural diseases were included; of the latter eight subjects suffered from asbestosis. Controls were 129 male subjects without any lung disease. No significantly elevated or decreased serum values for p53 protein, EGF-R, or anti-p53 antibodies as a function of histological tumour type, age, or degree and type of exposure (asbestos, smoking, ionizing radiation) could be found. The utility of p53-protein, EGF-R and anti-p53 antibodies as routine biomarkers for screening occupationally derived lung cancers is limited. © 1999 Cancer Research Campaign

Keywords: p53-protein, EGF-R, anti-p53 antibodies, serum, occupational, lung cancer

Full Text

The Full Text of this article is available as a PDF (103.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambs K. E., Takahashi A., Hering F., Costa S., Huber P. R. Epidermal growth factor receptor in adenocarcinoma of the kidney. Urol Res. 1989;17(4):251–254. doi: 10.1007/BF00262605. [DOI] [PubMed] [Google Scholar]
  2. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  3. Barker S., Vinson G. P. Epidermal growth factor in breast cancer. Int J Biochem. 1990;22(9):939–945. doi: 10.1016/0020-711x(90)90199-d. [DOI] [PubMed] [Google Scholar]
  4. Birrer M. J., Brown P. H. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res. 1992 May 1;52(9 Suppl):2658s–2664s. [PubMed] [Google Scholar]
  5. Brambilla E., Gazzeri S., Moro D., Caron de Fromentel C., Gouyer V., Jacrot M., Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. 1993 Jul;143(1):199–210. [PMC free article] [PubMed] [Google Scholar]
  6. Brandt-Rauf P. W., Smith S., Hemminki K., Koskinen H., Vainio H., Niman H., Ford J. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer. 1992 Apr 1;50(6):881–885. doi: 10.1002/ijc.2910500610. [DOI] [PubMed] [Google Scholar]
  7. Brandt-Rauf P. W. The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res. 1995 Dec;333(1-2):203–208. doi: 10.1016/0027-5107(95)00146-8. [DOI] [PubMed] [Google Scholar]
  8. Choi J. H., Oh J. Y., Ryu S. K., Kim S. J., Lee N. Y., Kim Y. S., Yi S. Y., Shim K. S., Han W. S. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer. 1997 May 15;79(10):1879–1883. [PubMed] [Google Scholar]
  9. Haeder M., Rotsch M., Bepler G., Hennig C., Havemann K., Heimann B., Moelling K. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 1988 Mar 1;48(5):1132–1136. [PubMed] [Google Scholar]
  10. Hanaoka T., Yamano Y., Katsuno N., Kagawa J., Ishizu S. Elevated serum levels of pantropic p53 proteins in chromium workers. Scand J Work Environ Health. 1997 Feb;23(1):37–40. doi: 10.5271/sjweh.176. [DOI] [PubMed] [Google Scholar]
  11. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  12. Horio Y., Suzuki H., Ueda R., Koshikawa T., Sugiura T., Ariyoshi Y., Shimokata K., Takahashi T., Takahashi T. Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene. 1994 Apr;9(4):1231–1235. [PubMed] [Google Scholar]
  13. Humbert M., Delattre R. M., Cerrina J., Dartevelle P., Simonneau G., Emilie D. Serum neopterin after lung transplantation. Chest. 1993 Feb;103(2):449–454. doi: 10.1378/chest.103.2.449. [DOI] [PubMed] [Google Scholar]
  14. Husgafvel-Pursiainen K., Kannio A., Oksa P., Suitiala T., Koskinen H., Partanen R., Hemminki K., Smith S., Rosenstock-Leibu R., Brandt-Rauf P. W. Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen. 1997;30(2):224–230. [PubMed] [Google Scholar]
  15. Levesque M. A., D'Costa M., Diamandis E. P. p53 protein is absent from the serum of patients with lung cancer. Br J Cancer. 1996 Nov;74(9):1434–1440. doi: 10.1038/bjc.1996.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lubin R., Zalcman G., Bouchet L., Trédanel J., Legros Y., Cazals D., Hirsch A., Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995 Jul;1(7):701–702. doi: 10.1038/nm0795-701. [DOI] [PubMed] [Google Scholar]
  17. Luo J. C., Zehab R., Anttila S., Ridanpaa M., Husgafvel-Pursiainen K., Vainio H., Carney W., De Vivo I., Milling C., Brandt-Rauf P. W. Detection of serum p53 protein in lung cancer patients. J Occup Med. 1994 Feb;36(2):155–160. doi: 10.1097/00043764-199402000-00010. [DOI] [PubMed] [Google Scholar]
  18. Lähdeaho M. L., Lehtinen T., Aine R., Hakala T., Lehtinen M. Antibody response to adenovirus E1b-derived synthetic peptides and serum levels of p53 in patients with gastrointestinal and other malignant lymphomas. J Med Virol. 1994 Aug;43(4):393–396. doi: 10.1002/jmv.1890430413. [DOI] [PubMed] [Google Scholar]
  19. Micelli G., Donadeo A., Quaranta M. The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. Cell Biophys. 1992 Aug-Dec;21(1-3):25–31. doi: 10.1007/BF02789475. [DOI] [PubMed] [Google Scholar]
  20. Mudenda B., Green J. A., Green B., Jenkins J. R., Robertson L., Tarunina M., Leinster S. J. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer. 1994 Jun;69(6):1115–1119. doi: 10.1038/bjc.1994.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nuorva K., Mäkitaro R., Huhti E., Kamel D., Vähäkangas K., Bloigu R., Soini Y., Päkkö P. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med. 1994 Aug;150(2):528–533. doi: 10.1164/ajrccm.150.2.8049841. [DOI] [PubMed] [Google Scholar]
  22. Partanen R., Hemminki K., Koskinen H., Luo J. C., Carney W. P., Brandt-Rauf P. W. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med. 1994 Dec;36(12):1324–1328. doi: 10.1097/00043764-199412000-00013. [DOI] [PubMed] [Google Scholar]
  23. Pavelic K., Banjac Z., Pavelic J., Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993 Jul-Aug;13(4):1133–1137. [PubMed] [Google Scholar]
  24. Preudhomme C., Lubin R., Lepelley P., Vanrumbeke M., Fenaux P. Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 1994 Sep;8(9):1589–1591. [PubMed] [Google Scholar]
  25. Rosenfeld M. R., Malats N., Schramm L., Graus F., Cardenal F., Viñolas N., Rosell R., Torà M., Real F. X., Posner J. B. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst. 1997 Mar 5;89(5):381–385. doi: 10.1093/jnci/89.5.381. [DOI] [PubMed] [Google Scholar]
  26. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., McIntosh J., Kurie J., Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993 May 15;53(10 Suppl):2379–2385. [PubMed] [Google Scholar]
  27. Schlichtholz B., Trédaniel J., Lubin R., Zalcman G., Hirsch A., Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer. 1994 May;69(5):809–816. doi: 10.1038/bjc.1994.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Segawa Y., Takigawa N., Mandai K., Maeda Y., Takata I., Fujimoto N., Jinno K. Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation. Lung Cancer. 1997 Mar;16(2-3):229–238. doi: 10.1016/s0169-5002(97)82785-7. [DOI] [PubMed] [Google Scholar]
  29. Sorscher S. M., Russack V., Graziano S., Cagle M., Feramisco J. R., Green M. R. Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer. Mod Pathol. 1995 May;8(4):450–455. [PubMed] [Google Scholar]
  30. Sozzi G., Miozzo M., Tagliabue E., Calderone C., Lombardi L., Pilotti S., Pastorino U., Pierotti M. A., Della Porta G. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res. 1991 Jan 1;51(1):400–404. [PubMed] [Google Scholar]
  31. Sugimura H., Weston A., Caporaso N. E., Shields P. G., Bowman E. D., Metcalf R. A., Harris C. C. Biochemical and molecular epidemiology of cancer. Biomed Environ Sci. 1991 Jun;4(1-2):73–92. [PubMed] [Google Scholar]
  32. Taylor J. A., Watson M. A., Devereux T. R., Michels R. Y., Saccomanno G., Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet. 1994 Jan 8;343(8889):86–87. [PubMed] [Google Scholar]
  33. Trivers G. E., Cawley H. L., DeBenedetti V. M., Hollstein M., Marion M. J., Bennett W. P., Hoover M. L., Prives C. C., Tamburro C. C., Harris C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst. 1995 Sep 20;87(18):1400–1407. doi: 10.1093/jnci/87.18.1400. [DOI] [PubMed] [Google Scholar]
  34. Trümper L., Jung W., Dahl G., Diehl V., Gause A., Pfreundschuh M. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol. 1994;5 (Suppl 1):93–96. doi: 10.1093/annonc/5.suppl_1.s93. [DOI] [PubMed] [Google Scholar]
  35. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]
  36. Weissfeld J. L., Larsen R. D., Niman H. L., Kuller L. H. Evaluation of oncogene-related proteins in serum. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):57–62. [PubMed] [Google Scholar]
  37. Wild C. P., Ridanpä M., Anttila S., Lubin R., Soussi T., Husgafvel-Pursiainen K., Vainio H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer. 1995 Jun 22;64(3):176–181. doi: 10.1002/ijc.2910640306. [DOI] [PubMed] [Google Scholar]
  38. Winter S. F., Minna J. D., Johnson B. E., Takahashi T., Gazdar A. F., Carbone D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992 Aug 1;52(15):4168–4174. [PubMed] [Google Scholar]
  39. Winter S. F., Sekido Y., Minna J. D., McIntire D., Johnson B. E., Gazdar A. F., Carbone D. P. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst. 1993 Dec 15;85(24):2012–2018. doi: 10.1093/jnci/85.24.2012. [DOI] [PubMed] [Google Scholar]
  40. Wynford-Thomas D. Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. J Pathol. 1991 Nov;165(3):187–201. doi: 10.1002/path.1711650302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES